Cytophage Technologies Ltd. Overview

Cytophage Technologies Ltd., a Canadian biotechnology company, is listed on the TSX Venture Exchange. The company is known for its specialization in developing innovative solutions for cellular processing and optimization. Its primary focus is on enhancing the efficiency and accuracy of blood cell counting and sorting techniques.

Recent Financial Performance

As of May 8, 2025, Cytophage Technologies Ltd. had a close price of CAD 0.24. The company’s stock has experienced significant fluctuations over the past year. The 52-week high was recorded at CAD 0.58 on May 20, 2024, while the 52-week low was CAD 0.125 on March 23, 2025. The market capitalization of the company stands at CAD 13,270,000.

Financial Ratios

The price-to-earnings (P/E) ratio for Cytophage Technologies Ltd. is currently -0.813756. This negative P/E ratio indicates that the company is not currently generating profits, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development.

Company Focus

Cytophage Technologies Ltd. is dedicated to advancing cellular processing technologies. The company’s efforts are particularly concentrated on improving blood cell counting and sorting methods, which are crucial for various medical diagnostics and treatments. By enhancing these techniques, Cytophage aims to contribute significantly to the field of biotechnology and healthcare.

Conclusion

Cytophage Technologies Ltd. continues to focus on its core mission of developing cutting-edge solutions in cellular processing. Despite the challenges reflected in its financial metrics, the company remains committed to innovation in the biotechnology sector, particularly in the area of blood cell technology.